latest news releases from the newsroom
Harsco Reports Record Diluted EPS of $0.99 for the 2005 Second Quarter, Up 32%; Company Raises 2005 Earnings Guidance
HARRISBURG, Pa., July 26, 2005 (PRIMEZONE) -- Worldwide industrial services and products company Harsco Corporation (NYSE:HSC) today reported record second quarter diluted earnings per share (EPS) from continuing operations of $0.99 for the second quarter of 2005, an increase of 32 percent from $0.75 in the second quarter of 2004. Income from continuing operations, also a record, was up 35 percent to $41.8 million from $31.0 million last year. Overall operating margins improved by approximately 140 basis points to 10.7 percent, up from 9.3 percent in last year's comparable quarter. Second quarter sales were up 13 percent to a record $696 million, compared with $618 million in the same period last year. Positive foreign currency translation contributed approximately $14 million to this year's second quarter sales and $1.3 million to pre-tax income.
eTelcharge.com Announces Spanish Version of the Website
DESOTO, Texas, July 26, 2005 (PRIMEZONE) -- eTelcharge.com (Pink Sheets:ETLC), www.etelcharge.com a financial diversified merchant service company, today announced that it will launch a Spanish version of its website on August 4, 2005, thus expanding its online presence in order to reach out to the millions of Spanish speaking Internet users.
DOR BioPharma, Inc
DOR BioPharma and Dowpharma Enter Into a Joint Development Agreement for BT-VACC, DOR's Oral Vaccine Against Botulinum Toxin Poisoning
MIAMI, July 26, 2005 (PRIMEZONE) -- DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") today announced it has entered into a joint development agreement with Dowpharma(sm), a business unit of The Dow Chemical Company (NYSE:DOW), to advance the development of DOR's proprietary oral botulinum vaccine, BT-VACC(tm). BT-VACC(tm) is designed to protect against exposure to botulinum toxin, which is one of five Category A bioterrorism threats identified by the U.S. government.
U.S. BioDefense, Inc. Retains Researcher Dr. Cyndi Chen, Ph.D. as Director of Stem Cell Research
CITY OF INDUSTRY, Calif., July 26, 2005 (PRIMEZONE) -- U.S. BioDefense (OTCBB:UBDE) announced today that is has retained Dr. Cyndi Chen, 26, as the new director of Stem Cell research. Dr. Chen will immediately begin to spearhead the Stem Cell Center of Excellence strategic plan and to evaluate the six (6) month option to license "Generation of Human Neural Crest Stem Cell Line and Its Utilization in Human Transplantation" world patent application WO 03/054202 A1 and U.S. patient application 5,958,767 and related applications with the University of British Columbia developed by Dr. Seung Kim in the Department of Neurology at UBC. U.S. BioDefense joins Asstrom (Nasdaq:ASTM), Geron (Nasdaq:GERN), and Viacell (Nasdaq:VIAC) in the industry and alongside StemCells, Inc. (Nasdaq:STEM) is the only other public company to focus on pioneering Neural Crest Stem Cell technology in the United States. A webcast powerpoint presentation by Dr. Chen will provide a layperson's guide to the breakthrough stem cell technology in the near future.